Each cancer subtype presents with its own challenges when it comes to breast cancer therapeutics; for example, in hormone receptor-positive cancers, mutations in molecular drivers have limited the success of treatment efficacy [44]. The gene discussed is NR4A1; the disease is breast carcinoma.